Covalon Presents Its Latest Antimicrobial Products at APIC

MISSISSAUGA, On, June 4, 2012 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced healthcare company, today announced that it is presenting its latest breakthrough antimicrobial products, including the recently United States FDA cleared IV Clear™, at the 2012 Association for Professionals in Infection Control and Epidemiology, Educational Conference and International Meeting ("APIC") from June 4 to 6 in San Antonio, Texas.

Covalon will be showcasing its latest products such as ColActive® Plus Ag, which is cleared for use by the FDA in the management of diabetic ulcers and other chronic wounds, IV Clear antimicrobial silicone adhesive dressing for vascular access and SurgiClear™, its unique antimicrobial transparent silicone adhesive surgical dressing.  Covalon will also present several vascular access, urological and implantable medical devices coated with Covalon's antimicrobial CovaCoat™ technology.

"APIC 2012 is a great opportunity for Covalon's North American, European, and Asian customers, medical professionals, and potential business partners to see our innovative infection prevention and control products" said Brian Pedlar, Covalon's Chief Executive Officer.

APIC's Annual Educational Conference and International Meeting is one of the largest annual gatherings of infection preventionists in the world. It showcases the latest innovative products, technologies and services and provides unparalleled opportunities to engage with infection prevention experts. The 39th Annual Educational Conference & International Meeting brings together professionals from across the healthcare continuum, with more than 200 companies and 2,700 attendees expected at this year's event.

To learn more about Covalon's products and services, please visit us at booth #235 in the Henry B. Gonzalez Convention Center in San Antonio, Texas from June 4 to 6, 2012 or contact Covalon directly:

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

 

Brian Pedlar
CEO, Covalon Technologies Ltd.

Email: [email protected]
Phone: [phone] x 233
Toll free: 1.877.711.6055
Fax: [phone]
Web site: www.covalon.com
Twitter: @covalon